Geron Corporation (NASDAQ: GERN) is a Healthcare company (Biotechnology) with a market capitalization of $644M. The Maz Rating grades it against the other companies in its sector.
Geron Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $1.00, Geron Corporation trades at 3.0x sales and 3.0x book value. Over the last twelve months it generated about $216M of revenue and a net loss of $45M. It runs a gross margin of 91.6%, an operating margin of -8.2% and a net margin of -23.0%. It shows return on equity of -22.3%, return on invested capital of -3.9% and a free cash flow yield of -14.1%. On the balance sheet: a debt-to-equity ratio of 0.53 and a current ratio of 6.31. Over the past 52 weeks the share price ranged from $0.84 to $2.01, with a beta of 0.61.
Geron Corporation does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 15 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Geron Corporation (GERN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 14.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 40.5% / 30% · Interest income / Revenue 5.03% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 14.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 34.4% / 33% · Receivables / Mkt Cap (36m) 5.48% / 49% · Interest income / Revenue 5.03% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 14.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 34.4% / 33.33% · Receivables / Mkt Cap (24m) 5.48% / 33.33% · Interest income / Revenue 5.03% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 40.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 58.8% / 33.33% · Receivables / Avg Assets (4Q) 8.50% / 33.33% · Interest income / Revenue 5.03% / 5% | Fail |
| FTSE | Debt / Total Assets 23.0% / 33.33% · (Cash+ST Inv) / Total Assets 54.7% / 33.33% · (Cash+Recv) / Total Assets 63.4% / 33.33% · Interest income / Revenue 5.03% / 5% | Fail |
No. As of September 2026, Geron Corporation (GERN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Geron Corporation is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 5.03% of each dividend: Geron Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.